70 related articles for article (PubMed ID: 22413504)
1. [Application of antidepressant to treat patients in the department of otolaryngology].
Goto F; Tsutsumi T; Ogawa K
Nihon Rinsho; 2012 Jan; 70(1):115-21. PubMed ID: 22413504
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
3. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
Roscoe JA; Morrow GR; Hickok JT; Mustian KM; Griggs JJ; Matteson SE; Bushunow P; Qazi R; Smith B
Breast Cancer Res Treat; 2005 Feb; 89(3):243-9. PubMed ID: 15754122
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment by paroxetine of delusional disorder, somatic type, accompanied by severe secondary depression.
Hayashi H; Akahane T; Suzuki H; Sasaki T; Kawakatsu S; Otani K
Clin Neuropharmacol; 2010; 33(1):48-9. PubMed ID: 19935408
[TBL] [Abstract][Full Text] [Related]
5. Induction of mania in depression by paroxetine.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
Grassi B; Gambini O; Garghentini G; Lazzarin A; Scarone S
Pharmacopsychiatry; 1997 Mar; 30(2):70-1. PubMed ID: 9131727
[TBL] [Abstract][Full Text] [Related]
7. Effects of selective serotonin reuptake inhibitor on treating tinnitus in patients stratified for presence of depression or anxiety.
Oishi N; Kanzaki S; Shinden S; Saito H; Inoue Y; Ogawa K
Audiol Neurootol; 2010; 15(3):187-93. PubMed ID: 19851065
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M
Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
[TBL] [Abstract][Full Text] [Related]
9. The role of paroxetine in fatigue and depression of patients under chemotherapeutic treatment.
Heras P; Kritikos K; Hatzopoulos A; Kritikos N; Heras V; Mitsibounas D
Am J Ther; 2013; 20(3):254-6. PubMed ID: 19262364
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
11. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
12. Paroxetine serum concentrations in depressed patients and response to treatment.
Gilles M; Deuschle M; Kellner S; Shams M; Krumm B; Härtter S; Heuser I; Hiemke C
Pharmacopsychiatry; 2005 May; 38(3):118-21. PubMed ID: 15902581
[TBL] [Abstract][Full Text] [Related]
13. Time course of response to paroxetine: influence of plasma level.
Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine: a review of clinical experience.
Dunner D; Kumar R
Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
[TBL] [Abstract][Full Text] [Related]
15. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
[TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure.
Gottlieb SS; Kop WJ; Thomas SA; Katzen S; Vesely MR; Greenberg N; Marshall J; Cines M; Minshall S
Am Heart J; 2007 May; 153(5):868-73. PubMed ID: 17452166
[TBL] [Abstract][Full Text] [Related]
17. [The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine].
Poirier MF
Encephale; 1999 Jun; 25 Spec No 2():55-7; discussion 58-61. PubMed ID: 10434160
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
